Syntis Bio Taps Matthew Dallas as CFO
Syntis Bio, Inc. a clinical-stage biopharmaceutical company advancing novel oral therapeutics that leverage the small intestine, has appointed Matthew Dallas as Chief Financial Officer (CFO). “With Matt’s appointment, we continue to assemble a leadership …